Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - As China rolls out its 12th five-year economic development plan, the R&D-based Pharmaceutical Association Committee (RDPAC) - an industry association representing multinational biopharma companies in China - is suggesting a friendlier regulatory environment for foreign companies

You may also be interested in...



Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference

SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation

Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference

SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation

Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say

SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel